Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial

Video

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

Following results that were reported at the 2020 San Antonio Breast Cancer Symposium, investigators of the phase 3 RxPONDER trial (NCT01272037) hope to further evaluate the clinical benefit from the addition of chemotherapy to endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer and an Oncotype DX Recurrence Score between 0 and 25.

Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine as well as director of both the Glenn Family Breast Center and of breast medical oncology at Winship Cancer Institute of Emory University, spoke with CancerNetwork® about next steps following the phase 3 RxPONDER trial.

Transcription:

I have a lot of work to do. We were only reporting at about 50% of the events, so we’re still awaiting additional events. And we’ll put this out as data come. We’ll also be reporting things like quality-of-life outcomes and other end points. And then there’s also a translational medicine component to this where we’ve collected primary tissue and lymph nodes involved that weren’t involved, in the hopes that we could also look at additional predictors or prognostic signatures that can help inform this patient population and potentially future studies as well.

Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Related Content